Recent years have seen a growing number of randomized, double-blind, controlled, clinical trials on novel therapeutic approaches in SLE. [1] [2] [3] Among the currently ongoing trials are now at least two studying the effects of TNF inhibitors, namely infliximab and etanercept, both including patients with lupus nephritis (clinicaltrials.gov). This may come as a surprise for two reasons. On the one hand, the use of TNF blockers is still one of the most controversial issues among SLE clinicians. On the other hand, as rheumatologists, we have been using TNF blockade for inflammatory arthritis and although lupus arthritis often presents a major clinical challenge, both these trials include patients with lupus nephritis only. Therefore, it appears worthwhile to review the background leading to these decisions.
Safety
In essence, five risks have to be weighed up when TNF blockers are used in patients with SLE (Table 1) : TNF blockade can lead to antibodies against doublestranded DNA (dsDNA) and other nucleosome components, [4] [5] [6] [7] [8] as well as to anticardiolipin (aCL) antibodies, 7,9 which could induce (i) lupus flares and (ii) thrombotic events. In addition, TNF blockade could provoke (iii) severe infections, (iv) lymphomas, and possibly (v) solid tumours. In addition, infusion and injection site reactions can occur, but these do not relate to the pharmacological mode of action of the respective agents.
The fear of SLE flares was based on data from the New Zealand Black (NZB) x New Zealand White (NZW) F1 model, 10, 11 as well as TNF-deficient NZB mice, 12 and on observations that anti-dsDNA antibodies and drug-induced lupus can arise under TNF blockade in patients with other inflammatory diseases, as reviewed in this journal and elsewhere. [13] [14] [15] However, there were also two relief arguments to make: despite ongoing autoantibody formation, TNF levels are high in SLE sera and tissue, [16] [17] [18] in association with disease activity, and TNF-blocker induced lupus-like disease is usually mild and self-limiting. 15, 19 The limited experience with TNF inhibitors in SLE now shows somewhat discrepant findings: antibodies to dsDNA, as well as to chromatin and to histones, indeed increased following infliximab. 20 In contrast to most cases of patients with other inflammatory diseases, where IgM anti-dsDNA antibodies are far more likely, 4 patients with SLE, who had preformed anti-dsDNA antibodies, had increased IgG anti-dsDNA. 20 Moreover, these antibodies were of high avidity, as demonstrated by Farr assay. In most patients, a rather sharp peak was seen, but after stopping the short-term infliximab induction therapy, these autoantibodies fell back to baseline levels or lower levels. In contrast, in single patients treated for longer periods with infliximab, further increases in anti-dsDNA antibodies were observed. Nevertheless, no bona fide SLE flare was reported in relation to TNF blocker therapy so far. Thus, an increase in anti-dsDNA antibodies appears to be the rule but flares are not.
Similar to the situation with antibodies to chromatin components, TNF blockade can lead to an increase in aCL antibodies, and associated vascular events have been reported. Again, among patients with SLE treated with infliximab, transient increases in aCL were seen, and in patients with preformed aCL, these were (also) of IgG isotype. 20 In addition, as reported in abstract form, one patient with preformed aCL developed deep vein thrombosis after a transient increase in these antibodies. 21 These data suggest that patients with preformed aCL may be at increased risk and that appropriate anticoagulation may be required under and after TNF blockade.
Infections are frequent and an important cause of morbidity and mortality in SLE. 22, 23 Although TNF blockers appear fairly safe in other inflammatory diseases, they clearly increase the risk for infections with intracellular pathogens. [24] [25] [26] In addition, in patients with significant proteinuria, infliximab could be lost via the urinary tract and potentially affect local immunity against common pathogens there. In our safety trial, we have observed several urinary tract infections. 27 Further infections were reported in abstract form, including two cases of pneumonia. 21, 28 One of these (with Legionella) ended fatal, but the infection occurred in a patient under long-term infliximab therapy, who had previously been pre-treated with various regimens, including cyclophosphamide and rituximab. Although the limited number of cases requires caution in interpreting these data, it appears that infections may be a significant problem under longer term TNF blockade in SLE and urinary tract infections may occur frequently. These observations further support our original decision to use TNF inhibitors only as an induction regime and not for maintenance therapy.
The risk for lymphoma is likewise increased in SLE, 29, 30 as is the case for other autoimmune diseases, presumably due to ongoing lymphocyte activation. Although, by reducing inflammation, TNF blockers may have protective effect, they may also facilitate growth of malignant lymphocytes. 31, 32 As again reported in abstract form, one patient with SLE under long-term TNF blockade developed cerebral lymphoma. 21 This single case cannot prove an association, but caution is warranted.
Finally, from the Wegener's granulomatosis etanercept trial, it appears that TNF blockade could induce solid tumours when combined with cyclophosphamide. 33 Most likely, TNF blockers could interfere with the removal of cells after cyclophosphamide-induced strand breaks. Therefore, the combination of TNF blockade with cyclophosphamide appears quite risky, though even short intervals between cyclophosphamide and the start of TNF blockade may lead to a quite different picture. So far, no solid tumours have been reported in any patients with SLE under TNF blockers.
Preliminary efficacy
When safety data on TNF blockers in SLE are to be analysed with caution, given the very limited number of patients, this caution is even more important for evaluating preliminary efficacy. In fact, it will be on the controlled trials to give us answers on efficacy. However, some patterns have emerged and are worth discussing.
In lupus arthritis, TNF blockade appeared to behave quite similar to what was expected from the experience in other forms of arthritis, where remission is often achieved quite rapidly, but relapse is the rule few months after TNF blockade is stopped. 21, 27 In lupus arthritis, remission was achieved even more rapidly in the few patients treated, which may be due to different pathophysiological mechanisms underlying the clinical problem. On the other hand, relapses occurred approximately eight weeks after the last of four infusions. TNF blockade for lupus arthritis thus appeared to work, but would require continued treatment, which may be fraught with an increase in the risks for autoantibodies, infections, and perhaps lymphoma. 20, 21 Lupus nephritis, in contrast, appeared to respond quite differently. Although not all patients responded, those who may have long-term effects when azathioprine or mycophenolate mofetil (MMF) are maintained during and after an infliximab induction phase. 21, 27, 34, 35 In particular, proteinuria level dropped rapidly under four infusions of infliximab and stayed at the low level for up to several years in many patients. 21, 27 Additional infusions of infliximab did not appear to have additional beneficial effects on lupus nephritis. Therefore, induction therapy with infliximab, probably at a dose of 5 mg/kg, may be a valid option for some patients with lupus nephritis, especially patients in whom standard therapies have failed. In contrast to lupus arthritis, lupus nephritis apparently does not require continued TNF blocker therapy.
For other inflammatory manifestations of SLE, there is even less information. At least, TNF blockade appears to have beneficial effects on hemophagocytic syndromes. [36] [37] [38] Likewise, there are reports on beneficial effects on cutaneous lupus, 39, 40 which likely will translate to SLE skin manifestations. With all due caution, reports suggest that for both manifestations 
Trials
At the moment, two trials are actively recruiting patients (clinicaltrials.gov). In the United States, with the University of California in San Francisco as the lead centre, etanercept is being tested against placebo on the background of azathioprine, MMF, or mycophenolic acid. Patients in the active arm receive 50 mg etanercept weekly for 6 months. In this trial, which is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), patients with SLE with lupus nephritis and anti-dsDNA antibodies are being included. The primary endpoint is safety.
The Medical University of Vienna sponsors a trial in Austria, Germany, and the Netherlands, which is funded by Centocor. In this trial, the active arm uses the four times 5 mg/kg infliximab induction regimen of our first open label safety trial. Background therapy consists of azathioprine and low-dose corticosteroids. This trial includes patients with membranous lupus nephritis and persistent high-grade proteinuria despite corticosteroids and angiotensin-converting enzyme inhibitors. The primary endpoint is time to achieving a reduction in proteinuria to less than 1.5 g/day.
Thus, although there are significant differences, both trials focus on patients with lupus nephritis and both keep up background immunosuppression. The focus on nephritis, rather than arthritis, appears sensible because of the long-lasting remissions observed, together with concerns on the safety of long-term TNF blockade in SLE. In addition, lupus nephritis is the disease manifestation with the best established trial protocols in SLE.
Conclusions
The controversy on TNF blockade is not yet resolved, but accumulating data fill some of the gaps in our knowledge. In the open label experience, it appears that TNF blockade, in combination with azathioprine or MMF, may be used for induction therapy in lupus nephritis, with long-lasting benefits. Single case reports suggest that the same may be true for hemophagocytic syndromes and some skin manifestations. However, lupus arthritis can only be controlled by long-term therapy, which may be far more dangerous. While, despite transient increases in relevant autoantibodies, no SLE flares were reported so far, even under long-term therapy, severe infections and potentially also lymphoma are of concern if therapy is continued. The first controlled trials have started and will hopefully give us clear answers.
